Filing Flows › Comparisons › PTCT vs BBIO
PTC Therapeutics vs BridgeBio Pharma: PTCT and BBIO compared
PTC Therapeutics is the larger company: $358M of revenue in its latest quarter (Q3 2026) against $353M for BridgeBio Pharma (Q3 2026). BridgeBio Pharma is growing faster (+193% against +70% a year earlier). PTC Therapeutics is more profitable, with an operating margin of 7.0% against -3.3%.
Where the money goes: PTCT and BBIO
PTC Therapeutics (PTCT) · Q3 2026
PTC Therapeutics, Q3 2026: revenue $358M (+70% year over year), operating margin 7.0%, net loss $51.7M, operating cash flow −$25.3M. The chart follows the revenue to costs, profit and cash.
BridgeBio Pharma (BBIO) · Q3 2026
BridgeBio Pharma, Q3 2026: revenue $353M (+193% year over year), operating margin -3.3%, net loss $60.5M, operating cash flow −$44.2M. The chart follows the revenue to costs, profit and cash.
| PTC Therapeutics (PTCT) | BridgeBio Pharma (BBIO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 2026 |
| Revenue | $358M | $353M |
| Revenue growth, Y/Y | +70% | +193% |
| Operating margin | 7.0% | -3.3% |
| Net earnings | −$51.7M | −$60.5M |
| Net margin | -14.4% | -17.1% |
| Operating cash flow | −$25.3M | −$44.2M |
| Market value | $5.5B | $14.6B |
| Analysts’ mean target | $100.47 | $106.85 |
Where the revenue comes from
PTC Therapeutics
- Net product revenue: $276M (77%)
- Royalty revenue: $81.7M (23%)
- Collaboration and license revenue: $229K (0%)
BridgeBio Pharma
- Net product revenue: $253M (72%)
- License and services revenue: $79.3M (22%)
- Royalty revenue: $20.5M (6%)
Questions
Which is bigger, PTC Therapeutics or BridgeBio Pharma?
PTC Therapeutics is the larger company: $358M of revenue in its latest quarter (Q3 2026) against $353M for BridgeBio Pharma (Q3 2026).
Is PTC Therapeutics or BridgeBio Pharma growing faster?
BridgeBio Pharma is growing faster (+193% against +70% a year earlier).
Which is more profitable, PTC Therapeutics or BridgeBio Pharma?
PTC Therapeutics is more profitable, with an operating margin of 7.0% against -3.3%.
More: PTC Therapeutics earnings · how PTC Therapeutics makes money · BridgeBio Pharma earnings · how BridgeBio Pharma makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Oct 29, 2026; 10-Q filed Oct 29, 2026). Fiscal quarters can end on different dates. Not investment advice.